FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:302-303 January 15, 2009 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Yusuf, S. PubMed Citation

To the Editor: We have eagerly awaited the results of the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) Study (Sept. 18 issue),¹ since a significant benefit of angiotensin-receptor blockers (ARBs) was anticipated based on the findings of several other groups (Losartan Intervention for Endpoint Reduction in Hypertension [LIFE],² Morbidity and Mortality after Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention [MOSES],³ and Study on Cognition and Prognosis in the Elderly [SCOPE]).⁴ It was very disappointing to see that telmisartan therapy failed to meet the primary end point — a significant reduction in the rate of recurrent stroke. Furthermore, it . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.